androstane-3,17-diol has been researched along with Obesity, Morbid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Du, J; Ge, M; Mizraji, K; Niu, C; Segall-Gutierrez, P; Stanczyk, FZ; Tilley, I | 1 |
1 trial(s) available for androstane-3,17-diol and Obesity, Morbid
Article | Year |
---|---|
Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.
Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenedione; Biomarkers; Body Mass Index; Contraceptive Agents, Female; Dehydroepiandrosterone Sulfate; Drug Implants; Female; Humans; Medroxyprogesterone Acetate; Obesity; Obesity, Morbid; Sex Hormone-Binding Globulin; Subcutaneous Tissue; Testosterone; Time Factors; Young Adult | 2012 |